Axonics, Inc. (Nasdaq: AXNX) has announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (NYSE: BSX) for US$71 in cash per share, representing an equity value of approximately US$3.7 billion.
Latham & Watkins LLP represented J.P. Morgan Securities LLC, as financial advisor to Axonics, in the transaction with a corporate deal team led by New York/Orange County partner Charles Ruck and Bay Area partner Luke Bergstrom, with associate Eric Czubiak.
LEGAL DESIRE NEWSLETTER
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.